Yusuke Nakamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yusuke Nakamura has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Aritoshi Iida
Department of Genome Medicine Development, Medical Genome Center, National Center of Neurology and Psychiatry (NCNP), Kodaira, Japan
1 shared publication - Daisuke Igawa
Steel Research Laboratory, JFE Steel Corporation
1 shared publication - Hideyuki Aoki
Department of Chemical Engineering, Graduate School of Engineering, Tohoku University
1 shared publication - Junya Sato
Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Yokohama, Japan
1 shared publication - Katsushi Tokunaga
Genome Medical Science Project National Center for Global Health and Medicine, Japan Institute for Health Security Tokyo Japan
1 shared publication - Kazuhiko Yamamoto
RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
1 shared publication
Latest Publications
- Open Access
- 15 July 2024
- Published by Iron and Steel Institute of Japan in ISIJ International
- Vol. 64 (9) , 1367-1375
Three-Dimensional Evaluation of Internal Structure of Coke Made by Blending Non-coking Coal Using X-ray Computed Tomography
Image analysis was performed on the analytical objects constructed by X-ray computed tomography images of coke with anthracite as low swelling and softening-melting coal to evaluate the pore structure three-dimensionally. The sphericity of the pores was calculated based on the volume and surface area of the pores. Tracers were inserted into all anthracite particles to distinguish coke matrices derived from anthracite from those derived from coking coal. This is the first success in identifying coke matrices derived from coking coal and those derived from other carbon source. The sphericity of pores in the surrounding area of the coke matrix derived from anthracite and the area without coke matrix derived from anthracite was extracted from the analytical object. The surrounding area of the coke matrix derived from anthracite contained more low-sphericity pores compared to the area without coke matrix derived from anthracite. This may be due to the free expansion of the coking coal in the surrounding area of the anthracite since the anthracite does not soften or expand during carbonization. The coking coal expanded excessively to fill the voids between the particles, resulting in the bubbles bursting and generating connected pores.
- 15 July 2024
- Published by Iron and Steel Institute of Japan in ISIJ International
- Vol. 64 (9) , 1367-1375
Open AccessThree-Dimensional Evaluation of Internal Structure of Coke Made by Blending Non-coking Coal Using X-ray Computed Tomography
Image analysis was performed on the analytical objects constructed by X-ray computed tomography images of coke with anthracite as low swelling and softening-melting coal to evaluate the pore structure three-dimensionally. The sphericity of the pores was calculated based on the volume and surface area of the pores. Tracers were inserted into all anthracite particles to distinguish coke matrices derived from anthracite from those derived from coking coal. This is the first success in identifying coke matrices derived from coking coal and those derived from other carbon source. The sphericity of pores in the surrounding area of the coke matrix derived from anthracite and the area without coke matrix derived from anthracite was extracted from the analytical object. The surrounding area of the coke matrix derived from anthracite contained more low-sphericity pores compared to the area without coke matrix derived from anthracite. This may be due to the free expansion of the coking coal in the surrounding area of the anthracite since the anthracite does not soften or expand during carbonization. The coking coal expanded excessively to fill the voids between the particles, resulting in the bubbles bursting and generating connected pores.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in OncoImmunology
- Vol. 9 (1)
Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]
We had conducted phase 1/2 studies of cancer vaccination therapy using neo-tumor antigens in patients with refractory/persistent cervical cancer (CC) and ovarian cancer (OC) to assess the feasibility and efficacy. Enrollees must be refractory/persistent disease for usual treatments with Human Leukocyte Antigen-A*0201 or A*2402. The targets were epitope peptides obtained from driver genes in surviving pathways as follows: for CC A*0201, peptides from Up Regulating Lung Cancer 10 gene (URLC10) and Hypoxia-inducible gene 2 (HIG-2) and for OC A*0201, HIG2, VEGFR (vascular epithelial growth factor receptor) 1 and 2 were used. For CC A*2402, Forkhead Box M1 (FOXM1), Maternal Embryonic Leucine zipper Kinase (MELK), and Holliday Junction Recognition Protein (HJURP) were used. For OC A*2402, cocktails of peptides from FOXM1, MELK, HJURP, VEGFR1, and VEGFR2 were used. Subcutaneous administration was performed with adjuvant weekly. The toxicity profiles and tumor-response were analyzed in eight-week interval. Sixty-six patients were accrued, and 64 were evaluable for adverse events (AEs), and 35 for response. AEs of G2/3 dermatologic reaction (DR) of injection site had been identified in 15.6% and no other severe AEs were detected. Response rate in OC and CC were 22.9% and 20%, respectively. Median overall survival showed longer in performance status (PS) 0 (versus PS1/2), in CRP negative (versus positive) and in DR positive (versus negative) such as 8.7 m versus 1.2 m (p < .001), 8.8 m versus 3.0 m (p < .05) and 10.2 m versus 1.2 m (p < .001), respectively. In conclusion, our vaccination therapy was feasible and effective in this cohort of patients.
- 1 January 2020
- Published by Taylor & Francis in OncoImmunology
- Vol. 9 (1)
Open AccessAnti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]
We had conducted phase 1/2 studies of cancer vaccination therapy using neo-tumor antigens in patients with refractory/persistent cervical cancer (CC) and ovarian cancer (OC) to assess the feasibility and efficacy. Enrollees must be refractory/persistent disease for usual treatments with Human Leukocyte Antigen-A*0201 or A*2402. The targets were epitope peptides obtained from driver genes in surviving pathways as follows: for CC A*0201, peptides from Up Regulating Lung Cancer 10 gene (URLC10) and Hypoxia-inducible gene 2 (HIG-2) and for OC A*0201, HIG2, VEGFR (vascular epithelial growth factor receptor) 1 and 2 were used. For CC A*2402, Forkhead Box M1 (FOXM1), Maternal Embryonic Leucine zipper Kinase (MELK), and Holliday Junction Recognition Protein (HJURP) were used. For OC A*2402, cocktails of peptides from FOXM1, MELK, HJURP, VEGFR1, and VEGFR2 were used. Subcutaneous administration was performed with adjuvant weekly. The toxicity profiles and tumor-response were analyzed in eight-week interval. Sixty-six patients were accrued, and 64 were evaluable for adverse events (AEs), and 35 for response. AEs of G2/3 dermatologic reaction (DR) of injection site had been identified in 15.6% and no other severe AEs were detected. Response rate in OC and CC were 22.9% and 20%, respectively. Median overall survival showed longer in performance status (PS) 0 (versus PS1/2), in CRP negative (versus positive) and in DR positive (versus negative) such as 8.7 m versus 1.2 m (p < .001), 8.8 m versus 3.0 m (p < .05) and 10.2 m versus 1.2 m (p < .001), respectively. In conclusion, our vaccination therapy was feasible and effective in this cohort of patients.
- 11 November 2014
- Published by SAE International in SAE International Journal of Advances and Current Practices in Mobility
- Vol. 1
Model-Based Combustion Control of a HCCI Engine using External EGR and the Exhaust Rebreathed
To approach realization of Homogeneous Charge Compression Ignition (HCCI) combustion without external combustion ignition trigger, it is necessary to construct HCCI engine control system. In this study, HCCI research engine equipped with the EGR passage for external EGR and the two-stage exhaust cam for exhaust rebreathed. This system can control the mixing ratio of four gases (air, fuel, rebreathed EGR gas, external EGR gas) of in-cylinder by operating four throttles and fuel injection duration while maintaining acceptable pressure rise rate (PRR) and cycle-to-cycle variation of Indicated Mean Effective Pressure (IMEP), closed-loop control system designed by applying feedback variables (equivalence ratio, combustion-phasing, IMEP) for feedback control.Those control inputs (four throttles and fuel injection) has correlation mutually, control inputs cause interference, response become low and hunching occurs. Therefore, model-based control system with modern control theory which is multi-inputs-multi-outputs system has been constructed to control HCCI combustion. For easily constructing linear- quadratic-integral (LQI) controller, discrete model was designed by discretizing 1 cycle of HCCI combustion into 6 points that represent the control-oriented description of the HCCI engine as a thermodynamic system. Although the results from discrete model nearly match with that of experiments near the base condition, the errors became large as the control input separates from base conditions. Furthermore, we tried linearization of discrete model implementing Taylor expansion for LQI control system.
- 11 November 2014
- Published by SAE International in SAE International Journal of Advances and Current Practices in Mobility
- Vol. 1
Model-Based Combustion Control of a HCCI Engine using External EGR and the Exhaust Rebreathed
To approach realization of Homogeneous Charge Compression Ignition (HCCI) combustion without external combustion ignition trigger, it is necessary to construct HCCI engine control system. In this study, HCCI research engine equipped with the EGR passage for external EGR and the two-stage exhaust cam for exhaust rebreathed. This system can control the mixing ratio of four gases (air, fuel, rebreathed EGR gas, external EGR gas) of in-cylinder by operating four throttles and fuel injection duration while maintaining acceptable pressure rise rate (PRR) and cycle-to-cycle variation of Indicated Mean Effective Pressure (IMEP), closed-loop control system designed by applying feedback variables (equivalence ratio, combustion-phasing, IMEP) for feedback control.Those control inputs (four throttles and fuel injection) has correlation mutually, control inputs cause interference, response become low and hunching occurs. Therefore, model-based control system with modern control theory which is multi-inputs-multi-outputs system has been constructed to control HCCI combustion. For easily constructing linear- quadratic-integral (LQI) controller, discrete model was designed by discretizing 1 cycle of HCCI combustion into 6 points that represent the control-oriented description of the HCCI engine as a thermodynamic system. Although the results from discrete model nearly match with that of experiments near the base condition, the errors became large as the control input separates from base conditions. Furthermore, we tried linearization of discrete model implementing Taylor expansion for LQI control system.
- Open Access
- 14 July 2010
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (14) , 5829-5839
Cell-Permeable Peptide DEPDC1-ZNF224 Interferes with Transcriptional Repression and Oncogenicity in Bladder Cancer Cells
Bladder cancer is the second most common genitourinary cancer worldwide, yet its oncogenic origins remain poorly understood. The cancer-testis antigen DEPDC1 was shown recently to contribute to bladder cancer oncogenesis. In this study, we examined the biological functions of DEPDC1 and defined a potential therapeutic strategy to target this molecule. Coimmunoprecipitation and immunocytochemistry revealed that DEPDC1 interacted and colocalized with zinc finger transcription factor ZNF224, a known transcriptional repressor. Inhibiting this interaction with a cell-permeable peptide corresponding to the ZNF224-interacting domain in DEPDC1 induced apoptosis of bladder cancer cells in vitro and in vivo. By inhibiting DEPDC1-ZNF224 complex formation, this peptide triggered transcriptional activation of A20, a potent inhibitor of the NF-κB signaling pathway. Our findings indicate that the DEPDC1-ZNF224 complex is likely to play a critical role in bladder carcinogenesis. Cancer Res; 70(14); 5829–39. ©2010 AACR.
- 14 July 2010
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (14) , 5829-5839
Open AccessCell-Permeable Peptide DEPDC1-ZNF224 Interferes with Transcriptional Repression and Oncogenicity in Bladder Cancer Cells
Bladder cancer is the second most common genitourinary cancer worldwide, yet its oncogenic origins remain poorly understood. The cancer-testis antigen DEPDC1 was shown recently to contribute to bladder cancer oncogenesis. In this study, we examined the biological functions of DEPDC1 and defined a potential therapeutic strategy to target this molecule. Coimmunoprecipitation and immunocytochemistry revealed that DEPDC1 interacted and colocalized with zinc finger transcription factor ZNF224, a known transcriptional repressor. Inhibiting this interaction with a cell-permeable peptide corresponding to the ZNF224-interacting domain in DEPDC1 induced apoptosis of bladder cancer cells in vitro and in vivo. By inhibiting DEPDC1-ZNF224 complex formation, this peptide triggered transcriptional activation of A20, a potent inhibitor of the NF-κB signaling pathway. Our findings indicate that the DEPDC1-ZNF224 complex is likely to play a critical role in bladder carcinogenesis. Cancer Res; 70(14); 5829–39. ©2010 AACR.
- Open Access
- 25 January 2008
- Published by Springer Nature in Journal of Human Genetics
- Vol. 53 (2) , 151-162
A functional SNP in the NKX2.5-binding site of ITPR3 promoter is associated with susceptibility to systemic lupus erythematosus in Japanese population
Journal of Human Genetics, official journal of the Japan Society of Human Genetics, publishes original articles and reviews on all aspects of human genetics, including medical genetics and genomics
- 25 January 2008
- Published by Springer Nature in Journal of Human Genetics
- Vol. 53 (2) , 151-162
Open AccessA functional SNP in the NKX2.5-binding site of ITPR3 promoter is associated with susceptibility to systemic lupus erythematosus in Japanese population
Journal of Human Genetics, official journal of the Japan Society of Human Genetics, publishes original articles and reviews on all aspects of human genetics, including medical genetics and genomics